WuXi XDC, China, with full-scale 바카라 에볼루션 CRDMO operations, will launch new facility in Singapore… “Focus on strengthening partnerships with Korea customers”

[by Ji, Yong Jun] As a global leading CRDMO specializing in Bioconjugates, WuXi XDC recently announced plans to strengthen its technology collaboration and co-development partnership with Korean biotechnology firms, leveraging its 바카라 에볼루션 manufacturing facility in Singapore, set to be operational by end 2025. This strategic initiative aims to capture the growing demands for 바카라 에볼루션 manufacturing by global dual-sourcing manufacturing network , and further reinforce the company’s capabilities to empowering partners by offering a comprehensive ‘integrated CRDMO service’ that can provide integrated services from antibody discovery to conjugation technology, process development, and commercial-scale production.

WuXi XDC hosted the ‘Ignite Future CRDMO DAY in Seoul Conference’ for Korean biotechnology companies on May 9 at the Hotel Sofitel Ambassador Seoul in Jamsil, Songpa District, Seoul. During the event, the company highlighted its upcoming 바카라 에볼루션 manufacturing facility in Singapore, slated to begin operations in the first half of this year, and emphasized its commitment to positioning Korea as a strategic technology partner, rather than just a customer.

WuXi XDC, a specialized 바카라 에볼루션 & Bioconjugate CRDMO subsidiary of WuXi Biologics founded in 2021, has completed over 900 projects in collaboration with more than 500 global partners. To date, the company has helped customers submit 85 investigational new drug (IND) applications.

Its new commercial 바카라 에볼루션 manufacturing facility in Singapore's Tuas Biomedical Park is set to be operational this year, with a production capacity of up to 8 million vials annually. At the event, Jun Hu, Vice President of WuXi XDC, stated, "The Singapore campus, located in a major cluster for global pharmaceutical companies, is positioned to serve as a key global base for 바카라 에볼루션 manufacturing."

Antibody-drug conjugate (바카라 에볼루션) is one of the emerging 'new modalities’ (a new approach to new drug development), gaining significant attention worldwide. The 바카라 에볼루션 market is projected to expand over fivefold, from approximately USD 13.2 billion (KRW 18.4734 trillion) in 2024 to USD 66 billion by 2030. “Around 60% of 바카라 에볼루션 developers currently partner with contract development and manufacturing organizations (CDMOs),” Jun explained. “Ultimately, this trend is likely to drive continued growth in demand for 바카라 에볼루션 CDMO services.”

WuXi XDC places a strong emphasis on providing comprehensive ‘one-stop services.’ “바카라 에볼루션 development traditionally involves multiple vendors for processes such as antibody production, linker and payload synthesis, conjugation, formulation, and analytical testing,” Jun emphasized. “All of these processes can be managed within a single platform.”

WuXi XDC has developed two specialized platforms: 'WuXiDARx'which allows precise control of the ‘Drug-to-Antibody Ratio (DAR)’ without requiring antibody modification, and ‘X-LinC,’ novel thiol reactive connector platform. According to the company, WuXiDARx can produce 바카라 에볼루션s with target DAR values (e.g., 1, 2, 4, 6 ) with purity high as 95%. The X-LinC platform offers the advantage of providing plasma stability of 바카라 에볼루션 drugs for over 21 days and completing conjugation in less than an hour, significantly surpassing the capabilities of stable MSPHY series linkers.

“The use of 'WuXi Direct'enables high-precision conjugation of DAR values of 1, 2, 4 and 6 without the need for genetic modification of antibodies,” expressed Jiawei Lu, Head of Bioconjugation Discovery Service at WuXi XDC. DAR (Drug-to-Antibody Ratio) refers to the average number of drug molecules (small-molecular-weight toxic agents) attached to each antibody in an 바카라 에볼루션. For instance, a DAR of 4 indicates that, on average, four drug molecules are conjugated to each antibody.

WuXi XDC outlined its strategic vision to strengthen technology co-development partnerships with Korea, leveraging the upcoming launch of its 바카라 에볼루션 production facility in Singapore. The company aims to position itself as a partner supporting the development and production of 바카라 에볼루션s alongside Korean biotechnology companies.

WuXi XDC has formed strategic 바카라 에볼루션 development partnerships with Korean biotech companies, including LigaChem Biosciences (hereinafter referred to as LigaChem Bio), AbTis, and Celltrion. In February, the company signed an agreement with LigaChem Bio to expand the scope of co-development for 바카라 에볼루션 and is currently incorporating AbTis’ linker purification technology as a critical component of its manufacturing process.

“In addition to technology transfer between China and Singapore, we have extensive experience in supporting the relocation of our clients’ production bases to WuXi,” said Xudong Dai, head of Bioconjugation Process Development at WuXi XDC. “This capability enables us to effectively minimize the risks associated with the relocation process,” he added.